CKD Trials Across the Age Spectrum: Challenges & Opportunities for Drug Development

  • Designing the first global chronic kidney disease trial in children using Jardiance
  • Evaluating which clinical trial endpoints are clinically meaningful and acceptable to regulatory authorities for pediatric indications and labeling
  • Exploring surrogate biomarkers and adaptive endpoints to reliably gauge efficacy and safety when disease progression is slow
  • Maximizing real world data, trial design and drug development programs for future therapies in kidney disease